Literature DB >> 23971638

Cardiovascular complications in autosomal dominant polycystic kidney disease.

Tevfik Ecder1.   

Abstract

Cardiovascular complications are a major cause of morbidity and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD). Hypertension is a common finding of ADPKD occurring in 50-70% of patients before the impairment of renal function. Stimulation of the renin-angiotensin-aldosterone system plays a major role in the development of hypertension in ADPKD. Hypertension is associated with an increased rate of progression to end-stage renal disease and is the most important potentially treatable variable in these patients. Left ventricular hypertrophy, a major cardiovascular risk factor, is also common in patients with ADPKD. Both hypertension and left ventricular hypertrophy play a crucial role in the development of cardiovascular complications in these patients. Furthermore, endothelial dysfunction, impaired coronary flow velocity reserve, biventricular diastolic dysfunction, increased carotid intima-media thickness, and arterial stiffness are present even in young normotensive patients with ADPKD who have well-preserved renal function. These findings suggest that cardiovascular involvement starts very early in the course of ADPKD. Intracranial and extracranial aneurysms and cardiac valvular defects are other potential cardiovascular problems in patients with ADPKD. A multifactorial approach aiming at all cardiovascular risk factors, such as hypertension, smoking, dyslipidemia and obesity is extremely important in these patients. Early diagnosis and treatment of hypertension, with drugs that block the renin-angiotensin-aldosterone system, has the potential to decrease the cardiovascular complications and slow the progression of renal disease in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23971638     DOI: 10.2174/1573402111309010002

Source DB:  PubMed          Journal:  Curr Hypertens Rev        ISSN: 1573-4021


  26 in total

1.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

2.  Deletion of cardiac polycystin 2/PC2 results in increased SR calcium release and blunted adrenergic reserve.

Authors:  Elisabeth DiNello; Elisa Bovo; Paula Thuo; Thomas G Martin; Jonathan A Kirk; Aleksey V Zima; Quan Cao; Ivana Y Kuo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-18       Impact factor: 4.733

3.  Capillary endothelia from two ADPKD patients are polyploidy.

Authors:  Sarmed H Kathem; Wissam A AbouAlaiwi; Xiaolin Zi; Surya M Nauli
Journal:  Ann Clin Cytol Pathol       Date:  2016-04-25

Review 4.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

5.  Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Charity G Patterson; Kyongtae T Bae; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Ronald D Perrone; Theodore I Steinman; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2017

Review 6.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

7.  Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells.

Authors:  Viktor Tomilin; Gail A Reif; Oleg Zaika; Darren P Wallace; Oleh Pochynyuk
Journal:  FASEB J       Date:  2018-03-19       Impact factor: 5.191

Review 8.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 9.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

Review 10.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.